Navigation Links
Nephros and Chem-Aqua Announce Distribution Agreement
Date:2/4/2013

ing edge research facilities. Our state-of-the-art products are manufactured to rigorous ISO 9001 specifications. Our field representatives are well trained and backed by some of the most experienced water treatment specialists in the business. Our Total System Approach allows us to provide custom water treatment solutions that will make a bottom line difference to our customers' operations.

Chem-Aqua is the wholly owned water treatment subsidiary of NCH Corporation, a worldwide company that has been providing high-quality maintenance supplies, chemicals and services since 1919. Our Corporate Offices are located in Irving, Texas, USA. We have over 25 manufacturing plants and distribution centers worldwide, and can provide custom water treatment solutions in over 28 countries in North and South America, Europe, and Asia.  

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters.  Our filters, which we call ultrafilters, are primarily used in dialysis centers and healthcare facilities for the production of ultrapure water and bicarbonate.  Because our ultrafilters capture contaminants as small as 0.005 microns in size, they eliminate a wide variety of bacteria, viruses, fungi, parasites, and endotoxins harmful to humans.

All of our ultrafilters use a proprietary hollow fiber technology.  We believe the hollow fiber design allows our ultrafilters to be the only commercially available filters for healthcare applications that optimize the three elements critical to filter performance:

  • Filtration – as low as 0.005 microns
  • Flow rate – minimal disruption
  • Filter life – up to 12 months

By comparison, competitive filters on the market today are typi
'/>"/>

SOURCE Nephros, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nephros Reports Third Quarter 2012 Financial Results
2. Nephros Reports Second Quarter 2012 Financial Results
3. Nephros Reports First Quarter 2012 Financial Results
4. Nephros Receives 510(k) Clearance for Hemodiafiltration System
5. Nephros Appoints John C. Houghton as President and Chief Executive Officer
6. Hologic Announces First Quarter Fiscal 2013 Operating Results
7. Cyberonics Announces Update On Hagerty Lawsuit
8. NewLink Genetics Corporation Announces Exercise of Underwriters Option and Closing of Public Offering of Common Stock
9. Medical Care Technologies Inc. Announces Financing Approval For Medical Equipment
10. Rockwell Medical Announces Iron Delivery Drug SFP Meets Primary Endpoint in PRIME Clinical Study Demonstrating Statistically Significant 37% Reduction in ESA Dose
11. Soligenix Announces Formation of Oral Mucositis Medical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... VIEJO, Calif., Oct. 12, 2011 Avanir Pharmaceuticals, Inc. ... affect (PBA) prevalence data from stroke survivors will be ... Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine in ... details about the data presentation at ACRM/ASNR Progress ...
... Good Start Genetics,™ Inc., an innovative molecular diagnostics ... screening, today announced that it will present results ... next-generation DNA sequencing platform at the Annual Meeting ...  ASRM will be held from October 15-19, 2011 ...
Cached Medicine Technology:Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference 2Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM) 2
(Date:4/23/2014)... Center researchers say clinical trials for a new ... are very promising. Patients treated with CPX-351, a ... are showing better responses than patients treated with ... "Acute myeloid leukemia is an aggressive blood cancer ... in older patients," explained Jeffrey Lancet, M.D., senior ...
(Date:4/23/2014)... to high-energy particles, simulating conditions astronauts would face on ... and slower reaction times, even when the radiation exposure ... impairments which affected a large subset, but far ... linked to protein changes in the brain, the scientists ... humans, suggest it may be possible to develop a ...
(Date:4/23/2014)... falls below normal levels are more likely to have ... disease and type 2 diabetes. A new simple screening ... and possible treatment is described in an article in ... from Mary Ann Liebert, Inc., publishers. The article is ... website at http://www.liebertpub.com/jmh . , ...
(Date:4/23/2014)... often displayed in the popular Swedish children,s TV ... high-sugar foods. A new study from the University ... children,s TV programmes as well as the link ... weight status. , Steingerdur Olafsdottir,s doctoral thesis focuses ... Swedish children,s TV show Bolibompa. Healthy foods dominated ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... half their concerns, so doctors should listen carefully, ... -- Older patients and surgeons don,t communicate effectively ... decision to have surgery can be particularly difficult ... School of Medicine study. , The researchers recorded ...
... Air-Pulse Autonomic Meditation Therapy is a non-denominational therapy that allows ... identity many feel when adopting ancient mind controlling meditative healings. ... ... 14, 2008 –- Dr. Ajrawat,s http://www.painmanagement.com/ [Air-Pulse Autonomic ...
... childhood asthma, but, when compared to girls, they are also ... have a decreased incidence of asthma in the post-pubertal years. ... asthma development, according to a prospective study that analyzed airway ... moderate asthma over a period of about nine years. , ...
... the past two decades, medication errors have dramatically increased. DecisionHealth, ... potentially harmful medication errors. , ... Gaithersburg, MD (PRWEB) ... Health Ledger,s recent drug overdose, increased dramatically over the past two ...
... Investigators from the Melbourne Center of the international Ludwig Institute ... reported that they have developed a test to predict whether ... metastatic Stage IV cancer and death. , More than ... has spread to the lymph nodes will typically have ...
... Investment to Close in September, Subject to Stockholder ... Potential Launch of MOXATAG(TM), GERMANTOWN, Md., Aug. ... a pharmaceutical company focused on,developing and commercializing novel ... the quarter ended June 30,2008., MiddleBrook reported ...
Cached Medicine News:Health News:Older Adults Reluctant to Question Surgical Treatment 2Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 2Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 3Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 4Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 5Health News:Asthma in boys may be just a phase, but for girls it may be there to stay 2Health News:Fatalities From Medication Errors at Home Up Dramatically - DecisionHealth Offers Solutions 2Health News:Fatalities From Medication Errors at Home Up Dramatically - DecisionHealth Offers Solutions 3Health News:Prototype test for predicting clinical outcome for melanoma patients 2Health News:Prototype test for predicting clinical outcome for melanoma patients 3Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 2Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 3Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 4Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 5Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 6Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 7Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 8Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 9Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 10Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 11Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 12Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 13
Infusion Cannula, 2.0mm....
Subretinal Fluid Cannula, Curved; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip; Curved at 65°....
Micro Vitreoretinal Cannula; Angled; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 65°, 1mm from Tip....
...
Medicine Products: